SCHEMBL51241

SCHEMBL51241

OCCCCCCC1CO1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
PRKD3 O94806 2/20 0.41
PRKCG P05129 2/20 0.41
PRKCB P05771 2/20 0.41
PRKCA P17252 2/20 0.41
PRKCH P24723 2/20 0.41
PRKCI P41743 2/20 0.41
PRKCE Q02156 2/20 0.41
PRKCQ Q04759 2/20 0.41
PRKCZ Q05513 2/20 0.41
PRKCD Q05655 2/20 0.41
PRKD1 Q15139 2/20 0.41
EPHX1 P07099 1/20 0.38
LMNA P02545 2/20 0.33
TSHR P16473 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HLCS P50747 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19297985 1.00
SCHEMBL5802259 1.00 ALDH1A1 (0.58) ALDH1A1PRKD3PRKCGPRKCBPRKCA
SCHEMBL51216 1.00 ALDH1A1 (0.58) ALDH1A1PRKD3PRKCGPRKCBPRKCA
SCHEMBL6431887 1.00 ALDH1A1 (0.58) ALDH1A1PRKD3PRKCGPRKCBPRKCA
SCHEMBL51708 1.00 ALDH1A1 (0.58) ALDH1A1PRKD3PRKCGPRKCBPRKCA
SCHEMBL9650577 1.00 ALDH1A1 (0.58) ALDH1A1PRKD3PRKCGPRKCBPRKCA
SCHEMBL19297986 1.00
SCHEMBL52306 1.00 ALDH1A1 (0.58) ALDH1A1PRKD3PRKCGPRKCBPRKCA
SCHEMBL11243835 1.00 ALDH1A1 (0.58) ALDH1A1PRKD3PRKCGPRKCBPRKCA
SCHEMBL2318247 1.00 ALDH1A1 (0.58) ALDH1A1PRKD3PRKCGPRKCBPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243220-A1 ATR INHIBITORS APREA THERAPEUTICS, INC. 2025-07-31 US disclosed
EP-4507791-A1 ATR INHIBITORS Aprea Therapeutics, Inc. (US) 2025-02-19 EP disclosed
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
WO-2023201320-A1 ATR INHIBITORS Atrin Pharmaceuticals LLC (US) 2023-10-19 WO disclosed
CN-109535707-B Pneumatic tire 横滨橡胶株式会社 2021-05-25 CN disclosed
EP-2508342-B1 INNER LINER FOR PNEUMATIC TIRE, AND METHOD FOR PRODUCING SAME KURARAY CO (JP) 2020-04-01 EP disclosed
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-03-12 US disclosed
EP-2508343-B1 MULTILAYER STRUCTURE AND METHOD FOR PRODUCING SAME KURARAY CO (JP) 2020-03-11 EP disclosed
EP-2554372-B1 MULTILAYERED STRUCTURE AND LAMINATE AND METHOD FOR PRODUCTION OF THE SAME KURARAY CO (JP) 2020-01-08 EP disclosed
EP-2857451-B1 PNEUMATIC TIRE YOKOHAMA RUBBER CO LTD (JP) 2019-05-08 EP disclosed
EP-0739351-B1 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS INC (US) 2002-04-10 EP disclosed
EP-0673956-B1 Binder for coating materials containing dispersed inorganic powder, coating material containing dispersed inorganic powder, and magnetic recording medium NIPPON ZEON CO (JP) 2000-01-05 EP disclosed
US-5886177-A ETHYLENE GLYCOL MONOMERS JOINED VIA STANDARD PHOSPHATE LINKAGES INCLUDING PHOSPHOROTHIOATE, PHOSPHODIESTER, AND PHOSPHORAMIDATE LINKAGES; USEFUL FUNCTIONAL GROUPS INCLUDE NUCLEOBASES AS WELL AS POLAR GROUPS, HYDROPHOBIC GROUPS ISIS PHARMACEUTICALS, INC. (US) 1999-03-23 US disclosed
EP-0739351-A4 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS INC (US) 1998-10-21 EP disclosed
US-5607772-A POLYURETHANE HAVING TERMINAL EPOXY GROUPS NIPPON ZEON CO., LTD. (JP) 1997-03-04 US disclosed
EP-0739351-A1 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 1996-10-30 EP disclosed
EP-0673956-A1 Binder for coating materials containing dispersed inorganic powder, coating material containing dispersed inorganic powder, and magnetic recording medium NIPPON ZEON CO., LTD. (JP) 1995-09-27 EP disclosed
WO-1995018820-A1 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 1995-07-13 WO disclosed
EP-0602209-A1 OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-06-22 EP disclosed
WO-1994001113-A1 OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1994-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A ALDH1A1 234/4885PRKD3 1080/4885PRKCG 1372/4885
US-20250243220-A1 ATR INHIBITORS ATR, CHEK1, CHEK2 ALDH1A1 3467/4885PRKD3 145/4885PRKCG 286/4885
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A ALDH1A1 234/4885PRKD3 1080/4885PRKCG 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.